Alcon shares rise 5.11% premarket after strong Q3 results driven by equipment growth and maintained guidance.

Alcon surged 5.11% in premarket trading following the release of strong third-quarter 2025 results, which highlighted 6% year-over-year revenue growth to $2.6 billion driven by accelerated equipment sales and ocular health demand. The company reported core diluted earnings per share of $0.79, maintained its full-year guidance despite prior profit warnings, and emphasized momentum from recent product launches like Unity VCS and PanOptix Pro. Analysts noted investor relief over the confirmed outlook amid challenges such as U.S. tariff pressures and stalled acquisition efforts. The surgical segment saw 6% growth, while Vision Care revenue rose 7%, underscoring improved market conditions and pricing power. Alcon’s ability to offset cost pressures and deliver robust performance in key markets reinforced confidence in its long-term prospects.